IFNG and Zygomycosis: Recently published in vitro and in vivo studies imply a benefit of checkpoint inhibition for salvage treatment of IFI.3-7 Here, we report the first immunosuppressed hematological patient receiving the immune checkpoint inhibitor nivolumab plus interferon gamma (IFN-γ) as salvage treatment for aspergillus and mucormycosis coinfection (Supplemental Figure 1, http://links.lww.com/HS/A132).